Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
Melanoma & Skin Cancers
-
-
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
-
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
-
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
-
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
-
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
-
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
-
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
-
Everolimus in Treating Patients With Stage IV Melanoma
Categories
Alliance Committee
Browse by Year